Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

J Yang, J Xu, W Wang, B Zhang, X Yu… - Signal transduction and …, 2023‏ - nature.com
Over decades, researchers have focused on the epigenetic control of DNA-templated
processes. Histone modification, DNA methylation, chromatin remodeling, RNA modification …

Cancer immune evasion through loss of MHC class I antigen presentation

K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021‏ - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Targeting the epigenetic regulation of antitumour immunity

SJ Hogg, PA Beavis, MA Dawson… - Nature reviews Drug …, 2020‏ - nature.com
Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

N Nagarsheth, MS Wicha, W Zou - Nature Reviews Immunology, 2017‏ - nature.com
The tumour microenvironment is the primary location in which tumour cells and the host
immune system interact. Different immune cell subsets are recruited into the tumour …

The emerging role of epigenetic therapeutics in immuno-oncology

MJ Topper, M Vaz, KA Marrone, JR Brahmer… - Nature Reviews …, 2020‏ - nature.com
The past decade has seen the emergence of immunotherapy as a prime approach to cancer
treatment, revolutionizing the management of many types of cancer. Despite the promise of …

The complementarity of DDR, nucleic acids and anti-tumour immunity

AVR Kornepati, CM Rogers, P Sung, TJ Curiel - Nature, 2023‏ - nature.com
Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

Emerging concepts for immune checkpoint blockade-based combination therapies

R Zappasodi, T Merghoub, JD Wolchok - Cancer cell, 2018‏ - cell.com
Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …

Prospects for combining targeted and conventional cancer therapy with immunotherapy

P Gotwals, S Cameron, D Cipolletta… - Nature Reviews …, 2017‏ - nature.com
Over the past 25 years, research in cancer therapeutics has largely focused on two distinct
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

W Zou, JD Wolchok, L Chen - Science translational medicine, 2016‏ - science.org
Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …

DNA damage and repair biomarkers of immunotherapy response

KW Mouw, MS Goldberg, PA Konstantinopoulos… - Cancer …, 2017‏ - aacrjournals.org
DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …